The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro

Molecular Medicine

Volumn 17, Issue 5-6, 2011, Pages 369-377

  Lewis, Eli C ^a,b   Blaabjerg, Lykke ^c   StØrling, Joachim ^c   Ronn, Sif G ^c   Mascagni, Paolo ^d   Dinarello, Charles A ^a   Mandrup Poulsen, Thomas ^c,e,f  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c STENO DIABETES CENTER   (Denmark)

^d Italfarmaco SpA   (Italy)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GIVINOSTAT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; NITRIC OXIDE; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG RESPONSE; FEMALE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; MOUSE; NEWBORN; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; SPLEEN CELL; STREPTOZOCIN DIABETES;

ANIMALS; CELL LINE; CELLS, CULTURED; CYTOKINES; FEMALE; GLUCOSE TOLERANCE TEST; HYDROXAMIC ACIDS; HYPERGLYCEMIA; IMMUNOBLOTTING; IN SITU NICK-END LABELING; INSULIN-SECRETING CELLS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; RATS; SPLEEN; STREPTOZOCIN;

EID: 79957949655     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00152     Document Type: Article

References (48)

1. Khan N, et al. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409:581-9.
2. Gerstner T, Bell N, Konig S. (2008) Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Expert Opin. Pharmacother. 9:285-92.
3. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89:1358-67.
4. Archin NM, et al. (2008) Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. Aids. 22:1131-5.
5. Atweh GF, Loukopoulos D. (2001) Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin. Hematol. 38:367-73.
6. Atweh GF, Schechter AN. (2001) Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr. Opin. Hematol. 8:123-30.
7. Marks PA, et al. (2001) Histone deacetylases and cancer: causes and therapies. Nature Rev. Cancer 1:194-202.
8. O'Connor OA, et al. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoy-lanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24:166-73.
9. Richon VM, Zhou X, Rifkind RA, Marks PA. (2001) Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol. Dis. 27:260-4.
10. Park JH, et al. (2004) Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. 10:5271-81.
11. Santini V, Gozzini A, Ferrari G. (2007) Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr. Drug Metab. 8:383-93.
12. Garcia-Manero G, et al. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodys-plastic syndromes. Blood. 111:1060-6.
13. Leoni F, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydrox-amic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. U.S.A. 99:2995-3000.
14. Reddy P, et al. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl. Acad. Sci. U.S.A. 101:3921-6.
15. Reilly CM, et al. (2004) Modulation of renal disease in MRL/lpr mice by suberoylanilide hy-droxamic acid. J. Immunol. 173:4171-8.
16. Glauben R, et al. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176:5015-22.
17. Leoni F, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1-15.
18. Leng C, et al. (2006) Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp. Hema-tol. 34:776-87.
19. Shein NA, et al. (2009) Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 23:4266-75.
20. Glauben R, et al. (2008) Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 57:613-22.
21. Carta S, et al. (2006) Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of micro-tubules. Blood. 108:1618-26
22. Bosisio D, et al. (2008) Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J. Leukoc. Biol. 84:1540-8.
23. Matalon S, et al. (2010) The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4+ T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J. Acquir. Immune Defic. Syndr. 54:1-9.
24. Guerini V, et al. (2008) The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 22:740-747.
25. Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452-8.
26. Donath M, et al. (2008) Xoma 052, an anti-IL-1beta antibody, in a double-blind, placebo con-trolled, dose escalation study of the safety and pharmacokinetocs in patients with type 2 diabetes mellitus, a new approach to therapy. Dia-betologia. 51 Suppl 1:433.
27. Larsen CM, et al. (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356:1517-26.
28. Larsen L, et al. (2007) Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia. 50:779-89.
29. Susick L, Veluthakal R, Suresh MV, Hadden T, Kowluru A. (2008) Regulatory roles for histone deacetylation in IL-1beta-induced nitric oxide release in pancreatic beta-cells. J. Cell Mol. Med. 12:1571-83.
30. Lundh M, et al. (2010) Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. Diabetologia. 53:2569-78.
31. Netea MG, et al. (2006) Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat. Med. 28:28.
32. Lewis EC, Dinarello CA. (2006) Responses of IL-18-and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor. Proc. Natl. Acad. Sci. U.S.A. 103:16852-7.
33. Fantuzzi G, et al. (2003) Generation and characterization of mice transgenic for human IL-18-binding protein isoform a. J. Leukoc. Biol. 74:889-96.
34. Fantuzzi G, Reed D, Dinarello CA. (1999) IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor. J. Clin. Invest. 104:761-7.
35. Larsen L, et al. (2005) Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor kappaB-mediated gene expression in insulin-producing INS-1E cells. Diabetologia. 48:2582-90.
36. Oldoni T, Furlan A, Monznani V, Dinarello CA. (2009) Decreased whole blood cytokine produc tion during a phase I trial of the histone deacety- lase inhibitor ITF2357 [abstract]. Cytokine. 48:120.
37. Sandberg JO, Andersson A, Eizirik DL, Sandler S. (1994) Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem. Biophys. Res. Commun. 202:543-8.
38. Bleich D, et al. (1995) Interleukin-1 beta regulates the expression of a leukocyte type of 12-lipoxy-genase in rat islets and RIN m5F cells. Endocrinology. 136:5736-44.
39. Mandrup-Poulsen T, Pickersgill L, Donath MY. (2010) Blockade of interleukin 1 in type 1 dia betes mellitus. Nat. Rev. Endocrinol. 6:158-66.
40. Marisa C, et al. (2005) MCP-1 and MIP-2 expression and production in BB diabetic rat: effect of chronic hypoxia. Mol. Cell Biochem. 276:105-11.
41. Cameron MJ, et al. (2000) Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J. Immunol. 165:1102-10.
42. Toubi E, Shoenfeld Y. (2004) The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity. 37:457-64.
43. Skov S, et al. (2003) Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood. 101:1430-8.
44. Reddy P, et al. (2008) Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118:2562-73.
45. Sun Y, et al. (2009) Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J. Immunol. 182:5899-903.
46. Bode KA, et al. (2007) Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology. 122:596-606.
47. Maedler K, et al. (2004) Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sul-fonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes. 53:1706-13.
48. Maedler K, et al. (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxic-ity in human pancreatic islets. J. Clin. Invest. 110:851-60.